A planned randomized trial will ask an intriguing question: Do COVID vaccines potentiate checkpoint inhibitors? January 09, 2026Vol.52 No.1By Sara Willa Ernst and Jacquelyn Cobb
Trials & Tribulations How a Montefiore Einstein screening program is changing the history of lung cancer in the Bronx January 09, 2026Vol.52 No.1By Brendon M. Stiles
Free Oncofertility coverage mandates expand to 21 states and DC as political momentum buildsGaps persist as patients face harrowing decisions and huge copays November 21, 2025Vol.51 No.43By Claire Marie Porter and Sara Willa Ernst
Regulatory News FDA to remove black box warnings on hormone therapy for menopauseTrump-era “gold standard science” is not to be confused with gold standard of scientific evidence November 14, 2025Vol.51 No.42By Claire Marie Porter
Trials & Tribulations Smoldering multiple myeloma: Rethinking the waiting game November 14, 2025Vol.51 No.42By C. Ola Landgren
Class action complaint alleging GRAIL insider fraud resubmitted after dismissal October 31, 2025Vol.51 No.40By Jacquelyn Cobb
Trials & Tribulations How GLP-1RA drugs are reshaping patient physiology and the future of oncology October 31, 2025Vol.51 No.40By Deborah Phippard
GRAIL to use new study results to seek FDA approval of Galleri MCD test October 24, 2025Vol.51 No.39By Jacquelyn Cobb
FreeTrials & Tribulations Experts warn that loss of carcinogen surveillance threatens to increase cancer incidence October 24, 2025Vol.51 No.39By David M. DeMarini, Rosalie Elespuru, Miriam C. Poirier and Errol Zeiger
Regulatory NewsTrials & Tribulations Under the lens: Taking a close look at the NIH and FDA declarations on animal-based research October 17, 2025Vol.51 No.38By Edison T. Liu
